Pomegra
Liquidia shares fell more than 50% after a Delaware court found Yutrepia infringed a United Therapeutics patent, while UTHR stock rose 12% on the ruling.
- Court found claims 1 and 14 of the '327 patent valid and infringed by Liquidia's Yutrepia.
- LQDA fell as much as 57% to $30.26; UTHR gained 12.3% to $540.54.
- Liquidia will appeal and ask the FDA to remove the PH-ILD indication from Yutrepia's label.
Lead
Liquidia (NASDAQ: LQDA) lost more than half its market value on Wednesday, September 30, 2026, after the U.S. District Court for the District of Delaware ruled that its dry-powder drug Yutrepia infringes a patent held by United Therapeutics (NASDAQ: UTHR). The stock fell about 25% in the first reaction and deepened to a decline of roughly 57%, to $30.26, its lowest level in nearly four months. The move erased about $3.18 billion in market value. UTHR rose 12.3% to $540.54, a gain of about $60.What Did the Court Decide?
The court found that claims 1 and 14 of U.S. Patent No. 11,826,327 are valid and infringed by Liquidia. It invalidated the remaining claims asserted against the company. The '327 patent covers methods of treating pulmonary hypertension associated with interstitial lung disease (PH-ILD) using inhaled treprostinil delivered with specific dry-powder features.
The court also denied Liquidia's motion to strike evidence on patent ownership. It held that the company had adequate notice before trial and did not object in time. The parties must submit a proposed judgment, including remedies, within about one week.
Why Did Liquidia Shares Fall So Sharply?
Liquidia shares fell because the ruling puts Yutrepia's PH-ILD use, a central part of its commercial case, in legal jeopardy. Yutrepia competes directly with United Therapeutics' inhaled treprostinil drug Tyvaso. United Therapeutics has asked the court for injunctive relief that would restrict Yutrepia's availability, and a judgment on remedies is the next gate.
Liquidia said it will revise its regulatory filing to ask the FDA to remove the PH-ILD indication from Yutrepia's label. It will also pursue appeals. CEO Roger Jeffs said the company disagrees with the decision and is prepared to use all available appellate options. A narrower label would limit the patient population Yutrepia can address, which drove the selling.
How Did United Therapeutics Benefit?
The decision strengthens protection for Tyvaso, United Therapeutics' inhaled treprostinil franchise, in the PH-ILD market. UTHR's 12.3% gain reflects reduced competitive risk and a clearer path to enforcing its patent position. For investors in biotech company stocks, the case shows how a single patent ruling can move two rivals in opposite directions by billions of dollars in one session.
What Comes Next for Yutrepia?
The near-term sequence is set. The proposed judgment is due within a week, and the court will then decide on remedies, including whether to restrict Yutrepia's sales. Liquidia's label revision request at the FDA and its appeal to the Federal Circuit will run in parallel. The appeal will take months.
Yutrepia's use in pulmonary arterial hypertension is not addressed by the infringement finding on the '327 patent, which concerns PH-ILD. The scope of any injunction will therefore determine how much of Yutrepia's commercial opportunity survives. Until that ruling, both stocks are likely to trade on each procedural development.
Outlook
The Delaware ruling is a major setback for Liquidia and a clear legal win for United Therapeutics. Liquidia is shifting to damage control through a narrower label and an appeal. Remedies set in the coming weeks will determine whether the market's steep repricing of LQDA proves justified. UTHR's gain reflects stronger protection for Tyvaso in a growing inhaled-treprostinil market.
Mentioned tickers: LQDA, UTHR
